Cerebral Small Vessel DiseasesPhase 4NCT05578521
CerebrAlcare Pills on CereBral Small VesseL DiseasE(CABLE)
A Phase 4 study testing Cerebralcare pills in people with Cerebral Small Vessel Diseases, run by Beijing Tiantan Hospital at 1 site in China.
Trial summary
This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. Read more about this study
- Who is it for?
- Ages 45 to 75 years
- Conditions the study is for
- Cerebral Small Vessel Diseases
- What is being tested?
- Cerebralcare pills
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 114 participants
- Where
- 1 siteChina
- Study dates
- 5 Jun 2022to 31 Mar 2024
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 45-75 years old;
- No gender limitation;
- Cerebral small vessel disease is observed on brain MRI. White matter hyperintensity, Fazekas score ≥ 1 and combined more than 2 vascular risk factors (hypertension, hyperlipidemia, diabetes, obesity, smoking, and other vascular events except stroke) or combined with lacunar focus or Imaging findings suggest new subcortical lacunar infarction (within 7 days).
- Mild or moderate vascular cognitive impairment(16 ≤ MoCA ≤ 24 score, for patients with primary school degree or below,15 ≤ MoCA ≤ 23 score).
- Daily life independence (mRS ≤ 2).
- Sign informed consent.
Show all 9Show fewer
- Note:
- The imaging definition of small vessel disease refers to the strong guideline The total score of Fazekas was 6, which was the sum of Fazekas scores of subcortical and periventricular white matter lesions.
- New subcortical lacunar infarction: head MRI examination, subcortical, basal ganglia or brain stem DWI showed high signal (ADC diffusion limited) lesions with diameter < 20 mm, with or without corresponding clinical symptoms; There were new clinical symptoms. FLAIR sequence of head MRI showed flair hyperintense lesions (diameter < 20 mm) in subcortical, basal ganglia or pons.
Who cannot join
- Cerebral hemorrhage and subarachnoid hemorrhage occurred within 30 days.
- Symptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 50%; asymptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 70%.
- Coronary CTA or coronary angiography showed severe three vessel lesions or frequent angina pectoris within 30 days.
- Chronic kidney disease stage 4 or 5.
- Resistant hypertension which could not be controlled by medicine (SBP > 180mmHg or DBP > 110mmHg).
- Resistant hyperglycemia which could not be controlled by medicine(fasting blood glucose > 10mmol/L or HB1AC > 7%).
Show all 24Show fewer
- In acute cerebral infarction, the lesions showed high signal intensity on DWI, and the diameter was more than 20 mm or history of assive cerebral infarction within 30 days.
- Neurodegenerative diseases, such as AD and PD, have been diagnosed.
- There are clear non angiogenic white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy diseases, etc.
- Untreated cerebrovascular malformations or intracranial aneurysms (d > 3mm).
- Active gastrointestinal bleeding.
- Coagulation dysfunction or history of systemic bleeding.
- Hemorrhagic tendency (including but not limited to):PLT<100×109/L; heparin treatment within 48h; APTT ≥ 35s; current use of warfarin, INR > 1.7; current use of novel oral anticoagulants; current use of direct thrombin or factor Xa inhibitor.
- Severe hepatic or renal or heat insufficiency before randomization (severe hepatic insufficiency refers to ALT or AST > 2 times the upper limit of normal; severe renal insufficiency refers to serum creatinine> 1.5 times the upper limit of normal or eGFR<40 ml/min/1.73m2; severe heat insufficiency refers to NYHA stage 3 and 4).
- History of intracranial or intramedullary surgery within three months of randomization.
- The patient has used or is using chinese medicine with similar components to CerebrAlcare pill/granule (including Tianshu capsule, Toutongning capsule, Naoxintong capsule, Danzhen Toutou capsule, Yindanxinnaotong soft capsule, Naoxinqing Tablet, Bazhen pill and Shiquandabu pill) within 14 days.
- Definite indications for anticoagulation (suspicion of cardioembolism, e.g. atrial fibrillation, known heart valve prosthesis, atrial myxoma, endocarditis, etc.) or definite indications for dual antiplatelet therapy (e.g. recent coronary or cerebral artery stent implantation).
- Other surgical or interventional therapy planned within 1 year requiring experimental drugs discontinuation.
- Childbearing-age women who do not take effective methods of contraception without negative records of pregnancy tests.
- Known to be allergic to CerebrAlcare pill/granule.
- Contraindications of MRI examination (such as claustrophobia).
- With severe organic diseases, such as malignant tumor, the expected survival time is less than 1 years.
- Due to geographical or other reasons can not cooperate to complete the follow-up.
- Patients also participated in other clinical trials.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: CerebrAlcare Pills on CereBral Small VesseL DiseasE(CABLE):A Randomized, Double-blinded, Placebo-controlled, Multi-center Trial
This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.
Read the detailed description
Cerebral small vessel disease (CSVD) is prevalent in the aging population with insidious onset, almost affecting all levels of the brain vasculature, and challenges the social and healthcare system worldwide. CSVD is the major cause of 25% of strokes and more than doubles the odds of recurrent stroke; furthermore, it contributes to 45% of dementia cases and to global functional decline. However, an incomplete understanding of the pathogenesis of CSVD limits prevention and treatment efforts.
Cerebralcare Granule (CG) or Yangxue Qingnao granule, is a polyherbal medicine that was approved in 1997 by the China State Food and Drug Administration for the treatment of headaches and dizziness associated with cerebrovascular diseases. Cerebralcare pill is composed of 11 herbs. These herbs contain small molecules with various pharmacological actions. Cerebralcare pills have the same component as CG. Previous studies have demonstrated that CG significantly attenuated ischemia-reperfusion induced dysfunction, structural abnormalities in the microcirculation, and inflammatory injury. There are also studies confirming that CG also improved cognition function, improved cerebral microcirculation disorders, and hemodynamics.
Patients enrolled will be randomly assigned to either the treatment or control group to receive Brain Pill/Brain Pill placebo (from randomization to 6 months at a dose of 2 packs per day). Face-to-face interviews will be conducted at baseline, day 90, day 180, and 1 year after randomization.
The primary endpoint is the progression in cognition function which is assessed by Montreal Cognitive Assessment (MoCA) score. The secondary endpoints include changes in clinical characters, imaging markers (number and volume of white matter, number of lacunes, microbleeds, enlarged perivascular space ), hemodynamic parameters, Chinese medical symptoms, blood-brain barrier (BBB) permeability, proteomics, and inflammatory markers. The safety endpoints include severe hemorrhage events, symptomatic and asymptomatic intracranial hemorrhage, moderate hemorrhage, overall mortality, and serious adverse events.
- Conditions
- Cerebral Small Vessel Diseases
- Being tested
- Cerebralcare pills, Cerebralcare pills placebo
- Keywords
- cerebral small vessel diseases, Cerebralcare Pills, cognitive function, randomized controlled trial, multicenter study, double blind study, placebo-controlled
- Medical subject headings
- Cerebral Small Vessel Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cerebralcare pillsDrug
a dose of 2 packages, twice a day of Cerebralcare pills
Cerebralcare pills placeboDrug
Cerebralcare pills placebo will be administrated at the same rate with experimental group
| Study group | Role | What they receive |
|---|---|---|
| Cerebralcare pills placebo group | Placebo comparator | This group will receive Cerebralcare pills placebo, 2 packages, twice a day, from the day of randomization to 6 months. Receives: Drug: Cerebralcare pills placebo |
| Cerebralcare pills group | Experimental | This group will receive Cerebralcare pills, 2 packages, twice a day, from the day of randomization to 6 months. Receives: Drug: Cerebralcare pills |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression in cognition function
Cognition function assessed by Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome..
Measured: 6 months after randomization
Secondary outcomes (23)
Changes in both systolic and diastolic blood pressure
Including systolic and diastolic blood pressure (mmHg).
Measured: 3 months, 6 months and 1 year after randomization
Rey auditory verbal learning test(RAVLT)
The Rey Auditory Verbal Learning Test (RAVLT) provides a standardized procedure to evaluate a range of aspects of verbal learning and memory of supra-span lists of words. The test requires recalling as many words as possible in any order from a standard list of 15 unrelated words read out by the examiner. The total score ranges from 0-120, with a lower score indicating a worse outcome.
Measured: 3 months, 6 months and 1 year after randomization
Generalized Anxiety Disorder 7(GAD-7)
Generalized Anxiety disorder (GAD) is a widespread psychiatric syndrome involving significant consequences on people's health, with a total score of 21, where a higher score means a worse outcome. However, recent data show that this disorder has received little attention when compared to other anxiety disorders.
Measured: 3 months, 6 months and 1 year after randomization
Self-rating depression scale
The Zung Self-Rating Depression Scale (SDS) consists of 20 items with a Likert type scale after each item. Each item is rated from 1 to 4, with scores ranging from 20 to 80, where higher scores mean worse results
Measured: 3 months, 6 months and 1 year after randomization
Dizziness handicap inventory(DHI)
The DHI has 25 items with 3 response levels, sub-grouped into three domains: functional, emotional, and physical. A shortened version, the Dizziness Handicap Inventory short form (DHIsf), reduced to 13 items with 2 response levels, has been shown to compare favourably to the original version. Scores range from 0-100, with higher scores indicating worse outcomes.
Measured: 3 months, 6 months and 1 year after randomization
Headache impact test 6(HIT-6)
The HIT-6 consists of six items: pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress.Total HIT-6 score that ranges from 36 to 78, where a lower score indicates a greater impact of headache on the daily life of the respondent.
Measured: 3 months, 6 months and 1 year after randomization
EuroQol five dimensions questionnaire (EQ-5D)
It includes a descriptive system(DS) and a visual analogue scale(VAS). Two indicators are index value(ranged 0-1) and visual score(ranged 0-100) with higher scores corresponding to better health status.
Measured: 3 months, 6 months and 1 year after randomization
Stroop Color Word Test
The Stroop Color and Word Test (SCWT) is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. Shorter the test time, the better the outcome.
Measured: 3 months, 6 months and 1 year after randomization
Severity of white matter hyperintensities(WMHs)
Fazekas score is used to describe the different types of hyperintense signal abnormalities surrounding the ventricles and in the deep white matter. Periventricular hyperintensity (PVH) is graded as 0 = absence, 1 = "caps" or pencil-thin lining, 2 = smooth "halo", 3 = irregular PVH extending into the deep white matter. Separate deep white matter hyperintensity (DWMH) is rated as 0 = absence, 1 = punctate foci, 2 = beginning confluence of foci, 3 = large confluent areas. Higher scores indicats a worse outcome.
Measured: 6 months and 1 year after randomization
Changes of white matter hyperintensities(WMHs) volume
WMH volume is assessed on 3D fluid attenuated inversion recovery (FLAIR) sequence in mm3 or cm3. Larger volume indicates a worse outcome.
Measured: 6 months and 1 year after randomization
Number of lacunes
Lacunes were defined as rounded or ovoid lesions in the subcortical, basal ganglia, or brainstem, ranging from 3mm to 20mm in diameter, presenting with cerebral spinal fluid signal intensity on T2 and FLAIR, generally featuring a hyperintense rim on FLAIR and no increased signal on diffusion weighted imaging (DWI). Higher number of lacunae means a worse outcome.
Measured: 6 months and 1 year after randomization
Number of cerebral microbleeds
Cerebral microbleeds are defined as rounded, hypodense foci within brain parenchyma on susceptibi lity weighted imaging (SWI) sequence, up to 10 mm in diameter, and were differentiated from microbleed mimics based on current guidelines. Higher number of cerebral microbleeds means a worse outcome.
Measured: 6 months and 1 year after randomization
Number of enlarged perivascular space
Enlarged perivascular space was defined as small punctate or linear hyperintensities on T2 images in the basal ganglia or centrum semiovale. Higher number of enlarged perivascular spaces means a worse outcome.
Measured: 6 months and 1 year after randomization
Changes in hemodynamic parameters
Lower cerebrovascular reactivity (CVR), cerebral blood flow (CBF), and reduced radial peripapillary capillary network density, and parafoveal vessel densities of the superficial retinal capillary plexuses mean worse outcomes.
Measured: 6 months and 1 year after randomization
changes in Chinese medical symptoms
Chinese medical symptoms assessed by Blood Deficiency and Liver Hyperactivity Syndrome score. Scores range 0-21 and higher scores mean a worse outcome.
Measured: 6 months and 1 year after randomization
Difference of recurrent stroke between groups
stroke included ischemic stroke, hemorrhagic stroke, TIA, et al.
Measured: 3 months, 6 months and 1 year after randomization
changes in Blood-Brain Barrier (BBB) Permeability between groups
BBB permeability is assessed by MRI and biomarker (including NSE, GFAP, S100β).
Measured: 6 months and 1 year after randomization
Compare protein profiles observed among different groups.
Blood was collected from the healthy (n=6), experimental (n=6) and placebo (n=6) groups at baseline, 3 months, and 12 months post-dosing. Alterations in protein profiles were detected by high performance liquid chromatography-mass spectrometry (HPLC-MS). GO classification and pathway enrichment were performed to analyse relevant protein changes. Serum metabolomics was determined using untargeted assays, and metabolite patterns in different groups were distinguished using orthogonal partial least squares analysis (OPLS-DA), compared with databases, and validated with the help of standards to finalise qualitative and quantitative analysis of metabolites and to identify differential metabolites. The Cell Counting Bead Analysis (CBA) Flex Set Flow Multifactor Assay Kit is used to detect serum levels of the inflammatory factors IL-1β, IL-6, IL-10, IL-12 and TNF-α. Western blot analysis is used to validate changes in the expression of 20 key proteins obtained from proteomic analysis.
Measured: 6 months and 1 year after randomization
Composite vascular events
Incidence of symptomatic stroke, myocardial infarction and vascular death.
Measured: 3 months, 6 months and 1 year after randomization
All-cause death
Deaths from all causes to the research subjects
Measured: 3 months, 6 months and 1 year after randomization
Moderate and/or severe hemorrhage events
According to Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) criteria which classifies the severity of bleeding complications as follows: 1) severe or life-threatening bleeding-intracranial bleeding or bleeding that causes substantial hemodynamic compromise requiring treatment; 2) moderate bleeding-bleeding which needs blood transfusion; 3) minor bleeding-other bleeding, neither requiring transfusion nor causing hemodynamic compromise.
Measured: 3 months, 6 months and 1 year after randomization
Symptomatic and/or asymptomatic intracranial hemorrhage
Measured: 3 months, 6 months and 1 year after randomization
Adverse events and severe adverse events
renal failure, hepatic failure, death.
Measured: 3 months, 6 months and 1 year after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2022
- Study start5 Jun 2022
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Mar 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cerebral Small Vessel DiseasesStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 114 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Tasly Pharmaceutical Group Co., Ltd
- Responsible party
- Principal investigator, yilong Wang, Beijing Tiantan Hospital
- Investigators
- Yilong Wang, PhD,MD, Principal investigator, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05578521
- Sponsor's protocol ID
- KY-2021-176-04
- Status last verified
- Oct 2022
- First submitted
- 24 Jul 2022
- Last updated
- 13 Oct 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhou M, Gong Y, Han S, Wang M, Gu W, Chen HS, Zheng W, Feng K, Wang D, Li H, Zheng Z, Pan Y, Chen W, Wang Y. CerebrAlcare Pills on CereBral Small VesseL DiseasE (CABLE) trial: rationale and design. Stroke Vasc Neurol. 2026 Apr 27;11(2):247-252. doi: 10.1136/svn-2024-003756.
PubMed 40897453
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CerebrAlcare Pills on CereBral Small VesseL DiseasE(CABLE):A Randomized, Double-blinded, Placebo-controlled, Multi-center Trial
- ClinicalTrials.gov ID
- NCT05578521
- Acronym / sponsor ID
- KY-2021-176-04
- Conditions
- Cerebral Small Vessel Diseases
- Keywords
- cerebral small vessel diseases, Cerebralcare Pills, cognitive function, randomized controlled trial, multicenter study, double blind study, placebo-controlled
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 114 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Collaborators
- Tasly Pharmaceutical Group Co., Ltd
- Study start
- 5 Jun 2022 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Mar 2024 (estimated)
- First posted
- 13 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.
Detailed description
Cerebral small vessel disease (CSVD) is prevalent in the aging population with insidious onset, almost affecting all levels of the brain vasculature, and challenges the social and healthcare system worldwide. CSVD is the major cause of 25% of strokes and more than doubles the odds of recurrent stroke; furthermore, it contributes to 45% of dementia cases and to global functional decline. However, an incomplete understanding of the pathogenesis of CSVD limits prevention and treatment efforts.
Cerebralcare Granule (CG) or Yangxue Qingnao granule, is a polyherbal medicine that was approved in 1997 by the China State Food and Drug Administration for the treatment of headaches and dizziness associated with cerebrovascular diseases. Cerebralcare pill is composed of 11 herbs. These herbs contain small molecules with various pharmacological actions. Cerebralcare pills have the same component as CG. Previous studies have demonstrated that CG significantly attenuated ischemia-reperfusion induced dysfunction, structural abnormalities in the microcirculation, and inflammatory injury. There are also studies confirming that CG also improved cognition function, improved cerebral microcirculation disorders, and hemodynamics.
Patients enrolled will be randomly assigned to either the treatment or control group to receive Brain Pill/Brain Pill placebo (from randomization to 6 months at a dose of 2 packs per day). Face-to-face interviews will be conducted at baseline, day 90, day 180, and 1 year after randomization.
The primary endpoint is the progression in cognition function which is assessed by Montreal Cognitive Assessment (MoCA) score. The secondary endpoints include changes in clinical characters, imaging markers (number and volume of white matter, number of lacunes, microbleeds, enlarged perivascular space ), hemodynamic parameters, Chinese medical symptoms, blood-brain barrier (BBB) permeability, proteomics, and inflammatory markers. The safety endpoints include severe hemorrhage events, symptomatic and asymptomatic intracranial hemorrhage, moderate hemorrhage, overall mortality, and serious adverse events.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cerebralcare pills placebo group | Placebo comparator | Drug: Cerebralcare pills placeboThis group will receive Cerebralcare pills placebo, 2 packages, twice a day, from the day of randomization to 6 months. |
| Cerebralcare pills group | Experimental | Drug: Cerebralcare pillsThis group will receive Cerebralcare pills, 2 packages, twice a day, from the day of randomization to 6 months. |
Who may qualify
- Ages
- 45 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- 45-75 years old;
- No gender limitation;
- Cerebral small vessel disease is observed on brain MRI. White matter hyperintensity, Fazekas score ≥ 1 and combined more than 2 vascular risk factors (hypertension, hyperlipidemia, diabetes, obesity, smoking, and other vascular events except stroke) or combined with lacunar focus or Imaging findings suggest new subcortical lacunar infarction (within 7 days).
- Mild or moderate vascular cognitive impairment(16 ≤ MoCA ≤ 24 score, for patients with primary school degree or below,15 ≤ MoCA ≤ 23 score).
- Daily life independence (mRS ≤ 2).
Key exclusion criteria (24 listed)
- Cerebral hemorrhage and subarachnoid hemorrhage occurred within 30 days.
- Symptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 50%; asymptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 70%.
- Coronary CTA or coronary angiography showed severe three vessel lesions or frequent angina pectoris within 30 days.
- Chronic kidney disease stage 4 or 5.
- Resistant hypertension which could not be controlled by medicine (SBP > 180mmHg or DBP > 110mmHg).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cerebralcare pillsa dose of 2 packages, twice a day of Cerebralcare pills | Drug | Cerebralcare pills group |
| Cerebralcare pills placeboCerebralcare pills placebo will be administrated at the same rate with experimental group | Drug | Cerebralcare pills placebo group |
Primary outcome
Progression in cognition function
Time frame: 6 months after randomization
Cognition function assessed by Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome..
23 secondary outcomes
Changes in both systolic and diastolic blood pressure
Time frame: 3 months, 6 months and 1 year after randomization
Rey auditory verbal learning test(RAVLT)
Time frame: 3 months, 6 months and 1 year after randomization
Generalized Anxiety Disorder 7(GAD-7)
Time frame: 3 months, 6 months and 1 year after randomization
Self-rating depression scale
Time frame: 3 months, 6 months and 1 year after randomization
Dizziness handicap inventory(DHI)
Time frame: 3 months, 6 months and 1 year after randomization
Headache impact test 6(HIT-6)
Time frame: 3 months, 6 months and 1 year after randomization
EuroQol five dimensions questionnaire (EQ-5D)
Time frame: 3 months, 6 months and 1 year after randomization
Stroop Color Word Test
Time frame: 3 months, 6 months and 1 year after randomization
Severity of white matter hyperintensities(WMHs)
Time frame: 6 months and 1 year after randomization
Changes of white matter hyperintensities(WMHs) volume
Time frame: 6 months and 1 year after randomization
Number of lacunes
Time frame: 6 months and 1 year after randomization
Number of cerebral microbleeds
Time frame: 6 months and 1 year after randomization
Number of enlarged perivascular space
Time frame: 6 months and 1 year after randomization
Changes in hemodynamic parameters
Time frame: 6 months and 1 year after randomization
changes in Chinese medical symptoms
Time frame: 6 months and 1 year after randomization
Difference of recurrent stroke between groups
Time frame: 3 months, 6 months and 1 year after randomization
changes in Blood-Brain Barrier (BBB) Permeability between groups
Time frame: 6 months and 1 year after randomization
Compare protein profiles observed among different groups.
Time frame: 6 months and 1 year after randomization
Composite vascular events
Time frame: 3 months, 6 months and 1 year after randomization
All-cause death
Time frame: 3 months, 6 months and 1 year after randomization
Moderate and/or severe hemorrhage events
Time frame: 3 months, 6 months and 1 year after randomization
Symptomatic and/or asymptomatic intracranial hemorrhage
Time frame: 3 months, 6 months and 1 year after randomization
Adverse events and severe adverse events
Time frame: 3 months, 6 months and 1 year after randomization
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2022.
- Derived from this study: PubMed 40897453Zhou M, Gong Y, Han S, Wang M, Gu W, Chen HS, Zheng W, Feng K, Wang D, Li H, Zheng Z, Pan Y, Chen W, Wang Y. CerebrAlcare Pills on CereBral Small VesseL DiseasE (CABLE) trial: rationale and design. Stroke Vasc Neurol. 2026 Apr 27;11(2):247-252. doi: 10.1136/svn-2024-003756.
- Individual participant dataSharing planned: No
Related trials for Cerebral Small Vessel Diseases
Recruiting
Task-Oriented Training Versus High-Intensity Gait Training in People With Chronic Stroke
Stroke, Hemiplegia
RecruitingPhase 3
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Fabry Disease
Not yet recruitingObservational study
Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke
Ischemic Stroke, Acute, Blood Pressure Variability
RecruitingPhase 3
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
Cerebral Small Vessel Disease, Ischemic Stroke
RecruitingObservational study
A Study of Patients With Fabry Disease (US Specific)
Fabry Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yilong Wang, PhD,MD principal investigator
Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Cerebralcare pills in people with Cerebral Small Vessel Diseases, run by Beijing Tiantan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression in cognition function (time frame: 6 months after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05578521, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2022.